Rossmed Ultracare Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.10 M
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 151.05%
- Profit Growth -201.60%
- Ebitda 39.54%
- Net Worth -181.74%
- Total Assets -20.19%
About Rossmed Ultracare
Rossmed Ultracare Private Limited (RUPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 December 2019 (Five years and one month 8 days old ). Its registered office is in Kozhikode, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jahangeer Kalachalilakath, Kooranthazhathuparambil Benny, Sani Varghese, and One other member serve as directors at the Company.
Company Details
-
Location
Kozhikode, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85320KL2019PTC060889
-
Company No.
060889
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Dec 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Rossmed Ultracare?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jahangeer Kalachalilakath
|
Director | 24-Dec-2019 | Current |
|
Kooranthazhathuparambil Benny
|
Director | 24-Dec-2019 | Current |
|
Sani Varghese
|
Director | 24-Dec-2019 | Current |
|
Pramod Kumar
|
Director | 24-Dec-2019 | Current |
Financial Performance of Rossmed Ultracare.
Rossmed Ultracare Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 151.05% increase. The company also saw a substantial fall in profitability, with a 201.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 181.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rossmed Ultracare?
In 2022, Rossmed Ultracare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Rossmed Lifesciences Private LimitedJahangeer Kalachalilakath is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rossmed Ultracare?
Unlock and access historical data on people associated with Rossmed Ultracare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rossmed Ultracare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rossmed Ultracare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.